CCR8+FOXp3+ Treg cells as master drivers of immune regulation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 23, 2017, Pages 6086-6091

  Barsheshet, Yiftah ^a   Wildbaum, Gizi ^a   Levy, Eran ^a   Vitenshtein, Alon ^a   Akinseye, Chika ^b   Griggs, Jeremy ^b   Lira, Sergio A ^c   Karin, Nathan ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b GLAXOSMITHKLINE   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CCL1; CD39; Chemokine; EAE; FOXp3

Indexed keywords

CCL1 CHEMOKINE; CD39 ANTIGEN; CHEMOKINE RECEPTOR CCR8; GRANZYME B; IMMUNOGLOBULIN; INTERLEUKIN 10; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; CCR8 PROTEIN, HUMAN; CCR8 PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; FOXP3 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; ANIMAL; C57BL MOUSE; IMMUNOLOGY; METABOLISM; UPREGULATION;

ANIMALS; CHEMOKINE CCL1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MICE; MICE, INBRED C57BL; RECEPTORS, CCR8; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 85020284500     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1621280114     Document Type: Article

References (63)

1. Silver PB, et al. (2015) Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. J Immunol 194:3011-3019.
2. Joller N, et al. (2014) Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40:569-581.
3. van Loosdregt J, et al. (2013) Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39:259-271.
4. Laurence A, Belkaid Y, O'Shea JJ (2013) A degrading view of regulatory T cells. Immunity 39:201-203.
5. Lowther DE, Hafler DA (2012) Regulatory T cells in the central nervous system. Immunol Rev 248:156-169.
6. Chaudhry A, et al. (2011) Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34:566-578.
7. Shevach EM (2009) Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30:636-645.
8. Wing K, Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7-13.
9. Arpaia N, et al. (2015) A distinct function of regulatory T cells in tissue protection. Cell 162:1078-1089.
10. Durant L, et al. (2010) Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32:605-615.
11. Sakaguchi S, et al. (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8-27.
12. Gagliani N, et al. (2013) Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19:739-746.
13. Groux H, et al. (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737-742.
14. Roncarolo MG, et al. (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28-50.
15. Wildbaum G, Netzer N, Karin N (2002) Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading. J Clin Invest 110:701-710.
16. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL (1994) Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 265:1237-1240.
17. Luster AD (1998) Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-445.
18. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610-621.
19. Proudfoot AE (2002) Chemokine receptors: Multifaceted therapeutic targets. Nat Rev Immunol 2:106-115.
20. Schall TJ, Proudfoot AE (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 11:355-363.
21. Salomon I, et al. (2002) Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 169:2685-2693.
22. Wildbaum G, Netzer N, Karin N (2002) Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol 168:5885-5892.
23. Zohar Y, et al. (2014) CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest 124:2009-2022.
24. Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N (2008) CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med 205:2643-2655.
25. Freeman CM, et al. (2005) CCR8 is expressed by antigen-elicited, IL-10-producing CD4+CD25+ T cells, which regulate Th2-mediated granuloma formation in mice. J Immunol 174:1962-1970.
26. Roos RS, et al. (1997) Identification of CCR8, the receptor for the human CC chemo-kine I-309. J Biol Chem 272:17251-17254.
27. Inngjerdingen M, Damaj B, Maghazachi AA (2000) Human NK cells express CC che-mokine receptors 4 and 8 and respond to thymus and activation-regulated chemo-kine, macrophage-derived chemokine, and I-309. J Immunol 164:4048-4054.
28. Inngjerdingen M, Damaj B, Maghazachi AA (2001) Expression and regulation of chemokine receptors in human natural killer cells. Blood 97:367-375.
29. Chensue SW, et al. (2001) Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med 193:573-584.
30. Soler D, et al. (2006) CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. J Immunol 177:6940-6951.
31. Coghill JM, et al. (2013) CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. Blood 122:825-836.
32. Zamvil S, et al. (1985) T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317:355-358.
33. Islam SA, Ling MF, Leung J, Shreffler WG, Luster AD (2013) Identification of human CCR8 as a CCL18 receptor. J Exp Med 210:1889-1898.
34. Princen K, Hatse S, Vermeire K, De Clercq E, Schols D (2003) Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry. Cytometry A 51:35-45.
35. Krutzik PO, Trejo A, Schulz KR, Nolan GP (2011) Phospho flow cytometry methods for the analysis of kinase signaling in cell lines and primary human blood samples. Methods Mol Biol 699:179-202.
36. - naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875-1886.
37. Spinetti G, et al. (2003) The chemokine receptor CCR8 mediates rescue from dexamethasone-induced apoptosis via an ERK-dependent pathway. J Leukoc Biol 73:201-207.
38. D'Ambrosio D, et al. (1998) Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol 161:5111-5115.
39. Saraiva M, O'Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170-181.
40. Shevach EM, et al. (2006) The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 212:60-73.
41. Mascanfroni ID, et al. (2013) IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol 14:1054-1063.
42. Eruslanov E, et al. (2013) Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clin Cancer Res 19:1670-1680.
43. Qu C, et al. (2004) Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med 200:1231-1241.
44. Zingoni A, et al. (1998) The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 161:547-551.
45. Sebastiani S, et al. (2001) Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol 166:996-1002.
46. Elias KM, et al. (2008) Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111:1013-1020.
47. Nurieva R, et al. (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448:480-483.
48. Taflin C, et al. (2011) Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci USA 108:2891-2896.
49. Chalmin F, et al. (2012) Stat3 and Gfi-1 transcription factors control Th17 cell immunosup-pressive activity via the regulation of ectonucleotidase expression. Immunity 36:362-373.
50. Chaudhry A, et al. (2009) CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326:986-991.
51. Ciofani M, et al. (2012) A validated regulatory network for Th17 cell specification. Cell 151:289-303.
52. Littman DR, Rudensky AY (2010) Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140:845-858.
53. Hovhannisyan Z, Treatman J, Littman DR, Mayer L (2011) Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140:957-965.
54. Grinberg-Bleyer Y, et al. (2010) IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 207:1871-1878.
55. Tang Q, et al. (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28:687-697.
56. Saadoun D, et al. (2011) Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365:2067-2077.
57. Koreth J, et al. (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365:2055-2066.
58. Bluestone JA (2011) The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med 365:2129-2131.
59. Hoelzinger DB, et al. (2010) Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol 184:6833-6842.
60. Collison LW, Vignali DA (2011) In vitro Treg suppression assays. Methods Mol Biol 707:21-37.
61. Cacciatore JJ, Leonard EF, Chasin LA (2012) The isolation of CHO cells with a site conferring a high and reproducible transgene amplification rate. J Biotechnol 164:346-353.
62. Tompkins SM, et al. (2002) De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J Immunol 168:4173-4183.
63. Wildbaum G, Zohar Y, Karin N (2010) Antigen-specific CD25-Foxp3-IFN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17. Am J Pathol 176:2764-2775.